Skip to main content

Castle Creek Biosciences buys gene therapy company weeks after canceling IPO plans

The deal will enable the Exton company to expand both its new product pipeline and its technology platform.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.